NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Blair William & Co. IL

Blair William & Co. IL lessened its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 13.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 409,182 shares of the medical research company’s stock after selling 63,688 shares during the period. Blair William & Co. IL owned 0.32% of NeoGenomics worth $5,675,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NEO. Blue Trust Inc. boosted its stake in shares of NeoGenomics by 107.2% in the second quarter. Blue Trust Inc. now owns 2,331 shares of the medical research company’s stock valued at $32,000 after buying an additional 1,206 shares in the last quarter. Burkett Financial Services LLC purchased a new stake in shares of NeoGenomics during the 4th quarter worth $46,000. Quadrant Capital Group LLC grew its stake in shares of NeoGenomics by 22.0% during the 4th quarter. Quadrant Capital Group LLC now owns 4,900 shares of the medical research company’s stock worth $79,000 after purchasing an additional 883 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of NeoGenomics by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,434 shares of the medical research company’s stock worth $136,000 after purchasing an additional 1,791 shares during the period. Finally, Banque Cantonale Vaudoise increased its holdings in shares of NeoGenomics by 10.2% in the 2nd quarter. Banque Cantonale Vaudoise now owns 17,575 shares of the medical research company’s stock valued at $244,000 after purchasing an additional 1,633 shares in the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on NEO. Benchmark reissued a “buy” rating and set a $18.00 price objective on shares of NeoGenomics in a report on Tuesday, July 30th. Needham & Company LLC reissued a “buy” rating and set a $19.00 price target on shares of NeoGenomics in a research note on Tuesday, July 30th. Finally, Stephens reaffirmed an “overweight” rating and issued a $19.00 price objective on shares of NeoGenomics in a research note on Tuesday, July 30th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $19.89.

NeoGenomics Trading Down 1.2 %

Shares of NeoGenomics stock opened at $16.28 on Friday. NeoGenomics, Inc. has a 1 year low of $11.03 and a 1 year high of $21.22. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.01 and a quick ratio of 1.93. The business has a 50 day moving average price of $16.05 and a 200 day moving average price of $14.95. The company has a market capitalization of $2.08 billion, a P/E ratio of -24.67 and a beta of 1.19.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Monday, July 29th. The medical research company reported $0.03 earnings per share for the quarter. NeoGenomics had a negative net margin of 12.50% and a negative return on equity of 2.72%. The firm had revenue of $164.50 million during the quarter, compared to the consensus estimate of $161.82 million. During the same quarter in the previous year, the company posted ($0.09) EPS. The firm’s revenue for the quarter was up 12.0% on a year-over-year basis. Sell-side analysts anticipate that NeoGenomics, Inc. will post -0.22 EPS for the current fiscal year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.